31 January 2017 - US Republican politician Tom Price got a privileged offer to buy an Australian biomedical stock at a discount, the company’s officials said, contrary to his congressional testimony this month.

The man tapped by President Donald Trump to be secretary of the Department of Health and Human Services testified in his Senate confirmation hearings on January 18 and 24 that the discounted shares he bought in Innate Immunotherapeutics, an Australian medical biotechnology company, “were available to every single individual that was an investor at the time”.

In fact, the cabinet nominee was one of fewer than 20 US investors who were invited last year to buy discounted shares of the company — an opportunity that, for Mr Price, arose from an invitation from a company director and fellow congressmen.

Read The Australian article